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1. INTRODUCTION 
In the last two decades, there was a change in the paradigm of drug research, and this 
worldwide tendency has reached CHINOIN R&D at the beginning of nineties. According to 
the former concept some or maximum some tens of compounds were synthesized and 
examined for in vivo pharmacological activity and for toxic effects. That is functional 
pharmacology and toxicology were the bases of a selection for further development. Very 
frequently, we knew nothing about the mechanism of action, and we had the first (negative) 
results on the absorption and metabolism of the compounds during the first clinical trials, 
when the company already spent a lot of money for the development. 
The principle of the new concept is mechanism-based or a molecular targeting research. 
Receptors, enzymes, ion-channels are the most frequent molecular targets, and the candidates 
are selected from some hundreds or thousands of compounds (compound-libraries, traditional 
synthesis and combinatorial chemistry provide more and more new chemical entities) based 
on their in vitro binding affinity. 
It takes 12 to 15 years to develop a new drug and bring it to market. For each successful new 
drug, roughly 5,000 compounds are evaluated in biochemical assays in vitro and in animal 
studies. Of these, only five will be found to be suitable for human clinical trials, and only one 
of the five will gain approval by the Food & Drug Administration as safe to market1. 
According to the above, it can be understood that drug research is very expensive. The costs 
of the development of a drug are estimated to be about $500 million (or higher), but these also 
include all the costs of unsuccessful projects and compounds. More than one-half of the 
money invested in pharmaceutical R&D is spent on molecules that never reach the clinic, and 
practically, "only" $50 million are the expenses of one successful product. The costs rise 
precipitously in the later stages of the drug development process. Candidates that fail late in 
the development stage incur huge, unrecoverable expenses. 
Roughly, 40 % of putative drug candidates - or new chemical entities - are rejected because 
of poor pharmacokinetics'. Similar data were published from the middle of nineties2'3. The 
rejected compounds do not make the grade in absorption, distribution, metabolism, or 
excretion. The 40 % rate is much higher than that of the compounds rejected due to the lack of 
human efficacy (30%), toxic effects in animals (11 %), adverse effects in man (10%), 
marketing reasons (5 %) or others (4 %). 
After surveying the above statistical data, it becomes clear why the change in the paradigm of 
the drug research involved the change in the role of the pharmacokinetic studies in the whole 
research and development process, and fortunately enough, the new methods and techniques 
provide the background for this new concept. 
When the new concept was accepted and applied in CHINOIN R&D - at the beginning of the 
nineties - a new approach in the pharmacokinetic and metabolism studies was also developed. 
This complex system of the ADME studies (absorption, distribution, metabolism and 
elimination) has been in use since then in the Pharmacokinetic and Metabolism Laboratory 
headed by me. 
Before discussing the details of the pharmacokinetics and metabolism, I have to make two 
important notes, which can explain some specialties of this thesis. On the one hand, the results 
of the drug research and especially those before patenting the best candidates are highly 
confidential. Too much money is spent on a drug, and the competition is rather strong, too. 
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For these reasons no publication is generally allowed at this stage. This is why the results of 
our work related to the discovery phase were not published; only some obscure hints were 
presented as examples in symposia [XVIII, XVI]. On the other hand, drug research and 
development is not a job of lonely scientist. I have been the head of the Pharmacokinetic and 
Metabolism Laboratory since 1988, and my principal task is to manage the laboratory, that is 
to determine the system of the studies to be performed according to current scientific and 
regulatory requirements, and to ensure the conditions for the work. It is the task of my staff to 
perform certain studies, and they always do it rather high standards. Accordingly, the results 
of the studies performed after 1988, and I will present hereafter, are common results of a team, 
where my role is much rather the planning, management and evaluation of the studies than the 
experimental work. 
In this paper, I will 
• introduce the structure and scheduling the pharmacokinetic and metabolism studies, 
according to the new R&D approach 
• show some examples how pharmacokinetic and metabolism studies help the selection 
of the drug candidates, the synthesis of new compounds having more favorable 
features 
• present examples on the synthesis of radiolabeled tracer molecules 
• introduce studies having the "classical roles" of the ADME studies, that is on the 
preclinical and clinical studies required for the registration of the drugs 
2. PHARMACOKINETIC AND METABOLISM STUDIES 
The traditional role of the pharmacokinetic and metabolism studies was to clarify the 
absorption, distribution, biotransformation and excretion of the compounds selected for the 
development, in animal experiments then in clinical trials. The studies were initiated in the so-
called preclinical phase with the in vivo experiments in rats, mice and dogs. 
According to the new concept, the pharmacokinetic examinations are started already in the 
discovery phase, and the traditional role is supplemented by a new one: to help the selection of 
the drug candidates. Thus, a general scheme of the drug discovery process can be 
demonstrated as it is depicted in Figure 1. 
information information 
Metabolism 
Absorption 
Kinetics 
Potency 
Efficacy 
Selectivity 
Design 
and 
Synthesis 
compounds compounds 
Figure 1. General scheme of the drug discovery process4 
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In our laboratory, both roles, the traditional one to provide safety results for the first human 
use or for the registration, and the new one to help the selection of drug candidates, were parts 
of our activities. 
2.1. BIOANALYTICS 
The basis of almost all pharmacokinetic and metabolism studies is the bioanalytical method. 
In the sixties and seventies the use of test substances labelled with radioactive nuclides such 
as 3H, 14C, and sometimes 32S or 125I, and measurements based on the monitoring of the 
radioactivity were the most popular. Applying radiolabeled preparation, not only the 
unchanged molecule was measured, but also its metabolites containing the characteristic part 
where the radionuclide was built in. Due to this advantage, this analytical technique remained 
a good tool for the determination of mass balance and metabolic profile even today. However, 
this advantage is a kind of drawback of the technique. Measurement of radioactivity alone 
cannot distinguish the metabolites from the unchanged compound. This is the reason why 
measurement of radioactivity is combined with chromatographic techniques (HPLC, GC). 
Another disadvantage is that rather few compounds can be tested with this method, because 
the synthesis of the radiolabelled derivatives takes a lot of time and money. 
Today, when the number of the hit drugs is huge, it is impossible to make radiolabelled 
preparation from all of them; thus, quicker, cheaper and more selective methods are necessary. 
HPLC or LC-MS/MS and — less frequently — GC or GC-MS provide a good tool for the 
quick and relatively cheap assays. These techniques can be used from the beginning to the end 
of the drug research and development process. 
2.1.1. Synthesis of radiolabelled compounds 
Radionuclides used most commonly in the pharmacokinetic and metabolism studies are ,4C 
and H. These P-emitters have low energy radiation (0.018 MeV and 0.159 MeV for H and 
14C, respectively5), thus they can be administered into the living organisms without a 
significant risk of any damage of the tissues and organs. They also have a relatively or 
definitely long half-life (12.2 and 5730 years for 3H and 14C, respectively5), which is 
appropriate for the analytical purpose. 
The crucial point of the synthesis of a radiolabelled preparation is always the positioning of 
radionuclides. Sometimes not one single nuclide is built in a compound to have higher 
specific radioactivity (in this case two or more of the same nuclide are built in, e.g. two 3H) 
[IX], or to have the possibility to distinguish the parts of the molecule (in this case two 
different nuclides are used, e.g. one 14C and one 3H) [VI]. It is important that the radionuclide 
must be in a characteristic part of the molecule, so the potential metabolic pathways must be 
take in consideration before synthesis. It needs a very close cooperation between the synthetic 
chemists and the pharmacokineticians. 
I show two examples on the synthesis of radiolabelled preparation from our practice. One is a 
14C-labelled compound, [14C]AICA phosphate [I], the other is a tritium labelled compound, 
[3H]Ipriflavone [IX]. I will also show an example on the application of double-labelled 
preparations [VI]. 
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2.1.1.1. Synthesis of ,4C-labelled AICA phosphate [I] 
AICA [4(5)-Amino-5(4)-imidazolecarboxamide] phosphate was a promising liver protecting 
agent in the seventies and eighties, the development of which finally was stopped due to 
toxicological reasons. Nevertheless, in the seventies considerable efforts were made to clarify 
its pharmacokinetic and metabolism characteristics and l4C-labelled preparation was 
synthesized. (This synthesis was made in 1978, when I worked as guest researcher at the 
Radiochemical Department of the Institute for Drug Research). To be in a stable position, the 
radionuclide was built into the imidazole ring. For this, a new synthesis route was developed 
using [14C]potassium cyanide as starting material. The steps of the synthesis can be seen in 
Figure 2. More details can be found in a publication [I]. 
H SO - H C I 
K C N + NaCI + EtOH 2 — - — - HC: 
'OEt 
/ / N H H2N CONH2 
^ N H . H C I ^ N H , N F = H 
+ H C - N H 2 1\K / N H .HCI 
0 E t U o c 
H 
NH2 
H2N CONH2 H2N CONH2 H2N CONH2 
N ^ / N H .HCI N ^ ^NH.H 2 0 N ^ ^NH.H 3 P0 4 c c c 
H H H 
Figure 2. Synthesis route of [14C]AICA phosphate [I]. 14C-labelling is printed in red 
characters. 
2.1.1.2. Synthesis of 3H-labelled ipriflavone [IX] 
Ipriflavone (7-/sopropoxyisoflavone) is an original antiosteoporotic agent of CHINOIN Co. 
Ltd., which was extensively examined also in our laboratory6-7. For metabolism studies and to 
examine the mechanism of action, tritium labelled preparation was synthesized. However, for 
these studies a preparation with high specific activity was necessary. Depending on the 
synthesis route, one or two radionuclides could be built into the molecule. The steps of the 
synthesis can be seen in Figure 3. The details are published in a paper in 1999 [IX]. 
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Br2, pyridine 
AcOH 
Single labelled 
preparation 
/-PrBr, K 2 C0 3 
DMF 
Double labelled 
preparation 
Br2, pyridine 
CHCI3/ACOH 
3H2, PdO, TEA 
Figure 3. Synthesis routes of 3H-labelled ipriflavone [IX] 
2.1.1.3. Use of quasi-double-labelled preparation [VI] 
Selegiline ((-)-deprenyl, JUMEX®) is one of the most successful products of CHINOIN Co. 
Ltd. It is a selective and irreversible inhibitor of monoamine oxidase type B, and it is widely 
8 • • used for the treatment of Parkinson's disease . Chemically, selegiline has two characteristic 
parts. One is amphetamine-like group containing the phenyl ring, and the other is the 
propargyl part. Since N-depropargylation is a main metabolic pathway for selegiline [V, XI], 
it was important to know if unchanged compound and/or which metabolites can be found in 
the different tissues, and especially in the different regions of the brain. For this purpose,-two 
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different radioactive preparations, selegiline-propynyl-14C and selegiline-phenyl-3H were 
synthesized (Figure 4). Creating a quasi-double-labelled preparation by mixing the two single-
labelled materials, we could monitor the two characteristic parts of selegiline parallelly [VI, 
vn], 
? H S , C H 3 
CH2CH N 
C H 2 C = C - H 
Figure 4. Positions of the 3H and l4C (red) atoms in the quasi-double-labelled selegiline 
preparation 
2.1.2. Chromatographic bioanalytical methods [X, XIII] 
Today chromatographic techniques are the most commonly used tools in the pharmacokinetic 
and metabolism studies. Unfortunately, the most modern technique, LC-MS/MS has been 
missing from our portfolio so far, but HPLC-s and GC-s equipped with various detectors (UV, 
fluorescence, diode-array, radioactivity detectors for HPLC-s, and FID, NP, EC, MSD for 
GC-s) can also be used efficiently. 
The requirements for the bioanalytical methods are, however, different in the different phases 
of the research and development process. Less sensitive, but reproducible methods with 
relatively short run-time and with appropriate selectivity against the endogenous materials 
found in the biological matrices used are necessary for the assays in the discovery phase. For 
the determination of test materials in matrices from preclinical, and especially for 
toxicokinetic studies, as well as from clinical trials, the bioanalytical methods have to be fully 
validated and very sensitive. During the whole research and development process, often more 
methods are developed and validated for a compound, because getting on the development, 
first only the unchanged compound is measured, later on the pharmacologically active or toxic 
metabolites should be also determined. Different methods are maybe necessary for the 
determination of the test material in the various biological matrices (plasma, urine, tissues) 
and for different species (e.g. for rat, dog, and human). 
The simultaneous HPLC determination of ipriflavone and its seven metabolites7 [XIII] and the 
gas chromatographic method for the determination of deprenyl and its main metabolites9 [X] 
can be good examples for the chromatographic methods developed in our laboratory. 
2 . 2 . P H A R M A C O K I N E T I C A N D M E T A B O L I S M S T U D I E S IN T H E D I S C O V E R Y P H A S E 
Working according to the "molecular targeting research approach" — as it was already 
mentioned before — after the first biochemical screens, we know the mechanism of action 
and we know that the "hit" or "lead" compounds act on the target molecules in vitro. 
However, for the in vivo efficacy in human, the compound must be suited many requirements. 
It must reach the target (receptor or enzyme) unchanged, and stay there for long enough to 
interact with it. 
K > 
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The common pharmacokinetic and metabolism issues encountered during lead optimalization 
(to have the drug candidate) are concerned essentially with systemic exposure and the 
potential drug-drug interaction. 
Since more hundreds or thousands of compounds have to be tested for their pharmacokinetics 
and metabolism, high or at least medium throughput in vitro techniques must be used. It is not 
only financial and practical requirement, but the aspects of animal protection are also 
mandatory. 
The body is practically an infinite series of aqueous compartments bounded by lipid 
membranes, which membranes control the disposition of compounds. An optimal drug 
candidate has to be able to cross the membranes of the gastrointestinal tract (absorption), and 
different tissue membranes (distribution). The ability of the compound to cross these 
membranes is fundamental to reach the molecular target, as well as their presence at 
appropriate concentration. The optimal clearance of the compound resulting from metabolic 
and renal clearance is also essential. Too high clearance would cause short elimination half-
life and short duration of action, while a too low clearance has the risk of drug accumulation. 
To characterize the compounds synthesized for the lead optimalization, we examine the 
chemical stability, the absorption, the metabolic stability and the protein binding of candidate 
compounds. 
2.2.1. Chemical stability 
The aim of testing chemical stability is to know if the examined compound is stable enough in 
the experimental matrices and/or in the gastrointestinal tract, because the unchanged test 
compound must reach the molecular target. We cannot expect activity if the compound is 
destroyed before absorption. The primary matrices examined are as follows: 
• pH 7.4 TRIS/HC1 buffer used for the in vitro liver microsomal tests 
• artificial gastric juice (0.2 g NaCl, 0.32 g pepsin and 2.5 g of 10 % HC1 solution 
diluted with water up to 100 mL; pH = 2) 
• artificial intestinal juice (1.0 g KH2PO4 and 1.5 g pancreatin in 100 mL of water 
adjusted to pH 7.5 with 0.1 M NaOH solution) 
Stability of the compound is also tested in the vehicles used in the in vivo studies. 
2.2.2. Absorption 
From marketing point of view — based on the convenience of the application — the oral 
formulations are the most favorable, thus the development of an orally active drug is the 
primary aim of the pharmaceutical companies. 
An optimal drug candidate first has to be absorbed from the gastrointestinal tract. A 
compound is considered to be absorbed if it reaches the systemic circulation unchanged. The 
systemic exposure can be poor if the transport through the intestinal membranes is limited or 
the parent compound is metabolized by "first pass" metabolism. 
Several methods from in vitro to in vivo are used to assess the absorption of drug candidates. 
Recognizing that physicochemical properties are crucial in the absorption of a drug, the 
prediction based on some basic physicochemical parameters seems to be rather quick method. 
For example, Lipinski's Rule-of-Five is a very useful approach10. According to this paradigm, 
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poor intestinal absorption or permeability is expected if at least two parameters are out of 
range among of the following four ones: 
• the molecular weight is higher than 500 
• the number of hydrogen bond donors (sum of OH-s and NH-s) is higher than 5 
• the number of hydrogen bond acceptors (sum of N-s and O-s) is higher than 10 
• the calculated log P is higher than 5 
However, even if this theory is a good approach, it marks the boundaries only. 
The absorption of the compounds was formerly assessed mainly by their octanol-water 
partition coefficient (log D), or it was measured in different in vivo or ex vivo animal 
experiments, e.g. in isolated intestinal loops" or in intestinal perfusion techniques. Today one 
of the most widely applied method is the measurement of the permeability coefficient through 
a human colon carcinoma cell (CaCo-2) monolayer or its new subclone, CaCo-2/TC7. CaCo-
2/TC7 cells have the favorable feature that — under strictly controlled conditions — they 
differentiate as small intestine endothelial cells, forming a monolayer with tight junctions 
1 9 
among them. Figure 5. shows an electron microscopic picture of differentiated CaCo-2 cells , 
while Figure 6. presents a general setting of this absorption model. 
Figure 5. Electron micrograph of CaCo-2 cells12 
(mv = microvilli, tj = tight junction) 
The cells form a monolayer on a membrane; the test material is put into the apical medium, 
which represents the luminal side of the intestines. At appropriate time point(s), samples are 
taken from the basal medium to determine the quantity of the test material penetrated through 
the monolayer. 
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C A C O - 2 / T C 7 CELLS 
M E M B R A N E 
B A S A L CHAMBER 
Figure 6. Experimental setting up of CaCo-2/TC7 in vitro absorption model 
The monolayer formed by CaCo-2 cells has almost all the characteristics important for the 
absorption. It contains enzymes, which can metabolize the xenobiotics (exogenous 
compounds), active transporter molecules (e.g. P-glycoproteins), which can cause an efflux of 
the compounds penetrated the membranes, thus it can model all types of the absorption (para-
and transcellular, active and passive transport, etc.). Test materials are applied in solubilised 
form, because the primary aim is to determine if the compound penetrates the membranes or 
not. For solubilization, we often use limited amount of organic solvents such as methanol or 
dimethylsulfoxide, since — according to the general trend — less and less water-soluble 
compounds arrive for study. Applying the test compounds in suspension, we can study the 
possible limiting role of the poor water solubility in the transport of the compounds through 
the membranes. When we put the test material into the basal medium, and take samples from 
the apical chamber (reverse arrangement), we can examine the efflux processes. 
The penetration of the materials through CaCo-2 monolayer is characterized by the apparent 
permeability coefficient (Papp). 
Papp — 
dQ 1 
dt AC o 
where A is the surface of the monolayer, Co is the initial concentration of the test material in 
the apical chamber and is the amount of the test material passed to the basal chamber 
dt 
during the time period dt. This latter the following equation can be used: 
dQ _ C,*V 
dt t 
where C, is the concentration of the test material in the basal chamber at time t. V is the 
volume of the basal medium. 
Based on Papp values, the expected absorption of the test material can be assessed in human. 
Papp values of well-known drugs and chemicals, such as PEG4000, mannitol, terbutaline, 
amisulpride, furosemide, glutamine, alfuzosin, propranolol, metoprolol, verapamil, 
testosteron, antipyrine, mizolastine, and of some compounds developed in Sanofi-Synthelabo, 
such as SR140333, SR49059, SL25.1039, SR57746 and SR48692 were determined using the 
conditions detailed above. A sigmoid curve (Figure 7.) was prepared from these Papp values 
and the fraction of dose absorbed in vivo (F %) obtained from human investigations. This is 
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the basis of the categorization of the compounds tested. A compound is expected to be well 
absorbed from the human gastro-intestinal tract, if the Papp > 2*10~6 cm/s, and no or poor 
absorption is expected, if Papp < 1*10"7 cm/s. 
Figure 7. Correlation between the apparent permeability coefficient (Papp) and the fraction 
absorbed in vivo in human (F % values) 
2.2.3. Metabolism 
As regards in vivo activity, it is not enough if a compound is well absorbed from the 
gastrointestinal tract. It has to reach the target tissues unchanged, and it has to remain there 
unchanged for a certain time (it is not requested for the irreversible agonists or antagonists). 
About 90 % of the metabolic changes take place in the liver, but the kidneys, lungs, guts and 
blood (plasma) also can have significant metabolic activity. 
Among the drug-metabolizing enzymes, cytochrome P450 (CYP450) is the most important. It 
was discovered in 1954 — while rat liver microsomes were examined — as "an appearing 
strong band at 450 nm"13. Since then we could learn that CYP450 is a superfamily of 
monooxygenase enzymes found across all living organisms and is postulated to have evolved 
from a common ancestral gene. Today several hundreds of CYP450 enzymes are known. The 
enzymes are divided into four families, and numerous subfamilies. They belong to the same 
gene family (gene family 1, 2, 3, 4, etc.) if they exhibit more than 40 % amino acid sequence 
homology, while those, which display more than 60 % (some authors give lower, 55 % 
percentage) sequence homology, belong to the same subfamily (e.g. subfamily 2A, 2B, 2C, 
2D, etc.). However, among the more than 40 human CYP 450 enzymes known, only 
approximately ten have of importance in the metabolism of drugs. Table 1. summarizes the 
most important human CYP450 isoforms, as well as some of their characteristics, such as 
their abundance in the liver, proneness for polymorphism, inducibility. 
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Table 1. The known human cytochrom P450 isoenzymes and some of their characteristics15,16,14 
CYP450 
isoform 
Abundance 
in liver 
Ratio < 
% 
)f the drugs metabolized 
Examples 
Poly-
morphism 
Inducibility Inhibitors 
1A1 0 
9 
Benzo[a]pyrene -(?) Isosafrole, Smoke, Charcoal-broiled 
food, Phénobarbital, Omeprazole, 
TCDD 
1-ethynyl pyrene, Ciprofloxacin 
1A2 9 Caffeine, Acetaminophen, 
Phenacetine, Lidocain 
Furafylline, a-naphthoflavone 
1B1 <1 <1 Resveratrol, Chemical 
carcinogens 
Polyaromatic Hydrocarbons Tranylcypromine, coumarine 
2A6 4 1 Coumarine, Testosterone, 
Nicotine 
+ Phénobarbital (?) Tranylcypromine, ketoconazole, 
2A7 - - - - -
2B6 
<1 <1 
Cyclophosphamide, 
Diazepam, Cocaine 
Ethylmorphine, DDT 
-
Phenytoin, Clofibrate, Barbital, 
Dexamethasone, Phénobarbital 
Quercetin, Chloramphenicol, 
Secobarbital, Orphenadrine 2B7 
2C8 
16 15 
Benzphetamine, Taxol, 
Diazepam, Diclofenac, 
Ibuprofen, Nifedipine, 
Warfarin, Mephenytoin 
+ 
Dexamethasone, Phénobarbital, 
Rifampicine, Phenytoin, Secobarbital 
Sulfaphenazole, Erythromycine 
2C9 Sulfaphenazole, Amiodarone 
2C19 Ticlopidine, Ketoconazole, Diazepam 
2D6 2 30 Debrisoquine, Spartein, 
Metoprolol, Mexiletine 
+ - Quinidine, Desipramine, Fluoxetine, 
Pindolol, Simvastatin, Verapamil 
2E1 6 1 Paracetamol, Halothane, 
Theophylline 
Fasting, Acetone, Ethanol, Isoniazid, 
Rifampicine 
Disulfiram, Ciprofloxacin, Isoniazid 
3A3 
63 44 
Cortisol, Cyclosporin A, 
Ketoconazole, Nifedipine 
- Carbazepine, Cortisol, Phenytoin, 
Dexamethasone, Ketoconazole, 
Phénobarbital, Rifampicine, 
Troleandomycin 
Ketoconazole, Erythromycin, 
Cimetidine, Nifedipine, Naringenin, 
Troleandomycin, Amiodarone 
3A4 
3A5 Erithromycin, Midazolam + 
3A6 ? ? 
3A7 ? + 
Isoenzymes having significant ro e in the human drug metabolism are boldfaced 
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Table 1. (Cont'd) The known human Cytochrom P450 isoenzymes and some of their characteristics15'16 
CYP450 
isoform 
Abundance 
in liver 
Ratio of the drugs metabolized Poly-
morphism 
Inducibility Inhibitors 
4A9 Arachidonic acid, Laurie Clofibrate, Ciprofibrate 
4A11 acid 
4B1 <1 <1 - -
4F2 
Ebastine 
4F3 
5 ? ? Thromboxane synthase ? ? ? 
7 Biosynthesis of steroid ? ? 
11A1 hormones such as 
11B1 ? ? progesterone, testosterone, corticosterone, estradiol 
? 
17A1 
19A1 
21A1 
27 
? No or conflicting data are available 
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The aim of the metabolic studies in the discovery phase is the assessment of the biological 
stability, that is to find a compound that can be expected to stay long enough in the organism, 
at the molecular target. The detailed studies of the metabolic processes are performed later, 
only with the selected compounds. For these reasons, the metabolic screens in the discovery 
phase are carried out using the most important biological matrices showing metabolizing 
activities, i.e. with the liver and plasma, and the experiments are aimed to answer the 
following questions: 
• How labile is the compound to metabolic conversion? 
• Are specific CYP isoforms such as CYP2D6 and CYP3A4 responsible for the 
biotransformation of the compound? 
• Is the compound a potent inhibitor of specific CYP isoforms such as CYP2D6 and 
CYP3A4? 
• Can glucuronidation be expected to be an important phase-2 metabolic process? 
Plasma has a special position in the pharmacokinetic and metabolism processes due to at least 
two reasons. On one hand, blood (plasma) is the transporter of the drugs (except of the 
topical-acting, not-absorbing compounds), all drugs stay in plasma for a certain time, thus it is 
important to know if a compound remains unchanged in the plasma inside the body. On the 
other hand, pharmacokinetic and pharmacodynamic parameters are generally determined by 
the plasma levels of the parent compounds and their metabolites (except of the irreversible 
inhibitors of receptors or enzymes). For this reason, serial blood samples are taken from the 
species examined after oral and intravenous administration, and the bioavailability of the 
drugs is assessed by comparing the plasma concentrations. It is important to know if a 
compound is stable in the plasma collected. 
Several techniques are used in the different research sites for the assessment of the hepatic 
metabolism. Precision-cut liver slices are almost complete systems, but their handling is 
somewhat difficult. Isolated liver cells can be easily used, and they are very popular in the 
drug discovery phase. They also can be considered as complete systems, having not only the 
microsomal but also cytosolic enzymes plus membranes and proteins participating in hepatic 
uptake. However, their preparation and maintenance are rather tedious. If we always prepare 
fresh primary cultures, the comparison of the results can cause problems, contrary, if we 
prepare a culture to use it for long period, the cells can lose their metabolic activities very 
soon. 
Liver microsomal preparations contain the majority of the metabolizing enzymes participating 
in the biotransformation of xenobiotics. This preparation can be prepared easily; its metabolic 
activity can be preserved by freezing. The diversity of the enzymatic activity among 
individuals (mainly in the case of human beings) can be diminished by preparation of pools. 
Owning to the ease of use, the primary assessment of the hepatic metabolism is often 
performed using liver microsomal preparations. 
2.2.3.1. Metabolic stability 
There are profound interspecies differences in CYP450 isoforms that make it almost 
impossible to extrapolate the findings from experimental animals to humans. For these 
reasons, we perform the in vitro metabolism studies in human preparation, as well as in 
preparations of animal species used in either the toxicological or pharmacological studies (rat, 
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mouse, dog, rabbit, hamster, guinea pig, gerbil). The metabolic stability of a drug in human 
and in animal species is compared, and we can get the first impression that the animal species 
to be used for the toxicological and pharmacological studies are adequate or not in this aspect. 
An example from our practice well demonstrates the above case. In the human leucocyte 
elastase (HLE) inhibitor project, CHINOIN researchers tried to find orally active inhibitors of 
HLE, supposing that these compounds are active in several illness including obstructive 
pulmonary diseases. The pharmacological test used also by the competitors was the so-called 
elastase-induced emphysema model in hamster17,18. It was surprising that a series of newly 
synthesized compounds were very active in the in vitro biochemical tests, but not in the 
hamster pharmacological model. The lack of the pharmacological activity even after 
intravenous administration excluded the first idea that the compounds had poor absorption. 
Later, the good absorption characteristics were confirmed by in vitro absorption studies. The 
in vitro metabolism studies in plasma (Figure 8.) and in liver microsomal preparations (Figure 
9.) gave the explanation. The metabolism of drug candidates, and especially that of SSR69071 
showed marked species differences. While SSR69071 was rather stable in human, dog and 
mouse plasma, as well as in human, dog, rat and mouse liver microsomal preparations, it was 
metabolically unstable in hamster and rat plasma, as well as in hamster liver microsomal 
preparation. Based on these results, change of the pharmacological species (and the 
pharmacological model) was suggested. Using rat and mouse models, a series of drug 
candidates having excellent in vitro biochemical activity, was also found to be active in the in 
vivo pharmacological tests. Finally, SSR69071 was selected for development. 
0 20 40 Time [minutes] 60 
Figure 8. Metabolic stability of an HLE inhibitor, SSR69071 in plasma obtained from human 
and animal species 
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Figure 9. Metabolic stability of an HLE inhibitor, SSR69071 in liver microsomal preparation 
obtained from human and animal species 
2.2.3.1.1. Chemical structure - metabolic stability relationship [XVIII] 
It is a key question in the discovery phase of the drug research and development, how can we 
modify the chemical structure of a so-called hit compound for getting more potent, or more 
selective, or better absorbed, or metabolically more stable derivatives. 
In the CHINOIN Co. Ltd., the aim of a project called prolylendopeptidase (PEP) inhibitors 
was to find potent, selective and orally active inhibitors of PEP enzyme. Following the 
synthesis of dozens of compounds, a lead compound having a bulky group (2-ethyl-
phtalimide) and a prolyl-pyrrolidine part was selected for further optimalization. One of the 
possible modifications was introducing a sulfur atom into the prolyl and/or the pyrrolidine 
group. Our task was to test if the new derivatives having sulfur atoms were metabolically 
stable enough. Table 2. shows the metabolic stability results obtained in human and mouse 
liver microsomal preparation [XVIII]. The results proved that the metabolic stability is 
decreased by the number of the sulfur atoms introduced. However, the stability returned, if 
oxidized forms of sulfur atom were built into the compounds (formation of sulfoxide and 
sulfone is certainly a pathway of their metabolism). 
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Table 2. Chemical structure — metabolic stability relationship in human and mouse liver 
microsomal fraction [XVIII] 
Chemical structure of the PEP 
inhibitors 
Half-life of the metabolic degradation 
[minutes] 
HUMAN MOUSE 
o 
365 55 
o 
136 34 
o 
87 15 
o 
330 231 
o 
210 96 
2.2.4. Protein binding 
Drugs bind to several biopolymers in the organisms. They bind to receptors and enzymes, 
which is the basis of their effect. They can also bind to the serum proteins, such as albumins, 
globulins, a-acyl-glycoprotein. The binding of a drug to serum proteins has a role in the 
transport of the drug, and in the formation of a depo. Thus, protein binding is a part of the 
distribution process. Furthermore, P-glycoproteins have a significant role in the membrane-
transport of the drugs, and especially in the excretion processes and the transport through the 
blood-brain barrier. 
There are several techniques for the examination of the binding of a drug to serum proteins. 
Equilibrium dialysis, ultracentrifugation, simple and dynamic ultrafiltration methods, gel 
chromatography and capillary electrophoresis are the most common methods. 
At discovery phase, protein binding tests are performed only in special cases, when — based 
on the in vivo pharmacological or toxicological observations — protein binding seems to be a 
significant factor in the efficacy of the drug tested. In our laboratory, ultrafiltration method 
was selected for the screens, due to its simplicity and its low time-consumption. 
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2.2.5 In vivo bioavailability 
In vivo bioavailability, in fact, is a kind of confirmation of the results of the in vitro absorption 
and in vitro metabolism studies. Using a minimum number of sampling times (4-5 sampling 
times) and a simple, partially validated analytical method for the assays, the absolute (e.g. oral 
versus intravenous) or relative (e.g. oral versus intraperitoneal) bioavailability is assessed. 
2 . 3 P R E C L I N I C A L P H A R M A C O K I N E T I C S A N D M E T A B O L I S M 
Pharmacokinetic and metabolism studies performed in the preclinical phase are necessary for 
having approvals to initiate the first human trials. In fact, these studies can be called as 
classical ADME studies. These belong to the so-called safety studies, which are performed in 
animal species. In order to demonstrate preclinical pharmacokinetic and metabolism studies, 
results obtained from experiments with an antitussive and antiasthmatic preparation are briefly 
described hereafter. Other examples will be shown only in certain cases. 
Antitussives are a traditional therapeutical field of CHINOIN Co. Ltd. Prenoxdiazine 
(LIBEXIN®) has been a widely used drug for years. In the eighties, CHINOIN started to 
develop new antitussive, antiasthmatic and mucoregulatory derivatives by combining the anti-
asthmatic theophylline and antitussive prenoxdiazine. Numerous very effective members of 
the series were synthesized and characterized19'20,21, out of them CHINOIN-170 (1,3-dimethyl-
7-[(5-methyl-l,2,4-oxadiazole-3-yl)methyl]-3,7-dihydro-l//-purine-2,6-dione) and CH-13584 
(3-methyl-7-[(5-methyl-l,2,4-oxadiazole-3-yl)methyl]-3,7-dihydro-l//-purine-2,6-dione)20,22,23 
were the most successful. 
CHINOIN-170 was studied in details for animal pharmacokinetics24, for animal metabolism25 
and for human pharmacokinetics26. Nevertheless, the project was stopped before registering 
the drug. 
CH-13584 was found to be a major metabolite of CHINOIN-170, and it was found to be much 
more effective19,20,25 than CHINOIN-170. Its non-clinical pharmacokinetic and metabolism 
characteristics were also studied in details [XII, XIV, XV], 
The chemical structure of the two compounds can be seen in Figure 10. 
Figure 10. Chemical structure of CHINOIN-170 (R = CH3) and CH-13584 (R = H) 
(* indicates the position of 14C labeling when radiolabeled preparation was used) 
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2.3.1. Toxicokinetics 
During the toxicological studies, the toxicological species are treated with rather high doses of 
the test material in order to clearly determine the highest dose having no toxicological effect, 
as well as the type of the toxic effects caused by the drug applied in higher doses than the "no-
effect dose". There are two main reasons why a drug does not show any toxic effect even at 
high doses. First, it can be really a non-toxic drug, or there is no exposition of the animal by 
the drug studied, e.g. due to the lack of the absorption. To demonstrate the exposure, and to 
determine if the absorption of the drug studied is proportional with the administered dose, 
toxicokinetic studies, as a support of toxicological and safety pharmacological studies, are 
performed. Carrying out of these trials is obligatory for all of the toxicological studies 
performed in compliance with the principles of "Good Laboratory Practices" (GLP)27'28. The 
toxicokinetic studies have also to be performed in compliance with the principles of GLP. 
2.3.1.1. Toxicokinetics of CH-13584 [XII] 
The oral toxicity of CH-13584 was found to be very low, thus, the toxicokinetic studies had to 
answer if this low toxicity was due to the lack of the absorption. 
Using a validated HPLC-UV method, concentration of the unchanged drug was measured in 
plasma samples obtained from male Wistar rats or from female beagle dogs. Both rats and 
dogs were treated orally with CH-13584 at single doses of 10, 100, 1000 and 2000 mg/kg. The 
results are summarized in Figure 11. and Figure 12. 
2000 mg/kg po 
1000 mg/kg po 
100 mg/kg po 
10 mg/kg po 50 -
0 • 
2 
• • » 
Time [hours] 6 0 4 
Figure 11. Plasma concentration versus time curve of unchanged drug in rat plasma after 
single oral administration of CH-13584 
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Figure 12. Plasma concentration versus time curve of unchanged drug in dog plasma after 
single oral administration of CH-13584 
Based on the maximal plasma concentration values (Cmax, Table 3.), it can be stated that 
absorption of CH-13584 is not linear within the dose range of 10 to 2000 mg/kg, either in rats 
or in dogs. However, the extent of the absorbed test material is increased up to 1000 mg/kg in 
rats, and up to 2000 mg/kg in dogs, but the linearity factors are far from 1.0. The results, 
however, prove that the reason of the low toxicity of CH-13584 is not the lack of the 
absorption. 
Table 3. Cmax values of CH-13584 in rats and dogs, and linearity factors of the absorption 
Dose 
[mg/kg] 
RATS DOGS 
C m a x 
[mg/L] 
Linearity* C m a x 
[mg/L] 
Linearity* 
/10 /100 /1000 no /100 /1000 
10 11.5 - - - 11.8 - - -
100 56.3 0.49 - - 58.6 0.49 - -
1000 201 0.17 0.36 - 109 0.09 0.19 -
2000 204 0.09 0.18 0.51 202 0.09 0.17 0.93 
Linearity was calculated by the equation of 
Dose(\)* C *Jj2) 
Dose(2)*C™(l) 
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2.3.2. Absorption, distribution and excretion 
The non-clinical pharmacokinetic and metabolism studies have to be performed in one rodent 
and in one non-rodent animal species. Rat and the dog are used as typical species, but others 
(e.g. mice and monkeys) may be also used, depending on the drug candidate and the 
therapeutic field. There is no strict regulation on the methods and scheduling of the studies, 
but it is clear that data should be provided on the absorption, distribution and elimination of 
the unchanged test material and its metabolites. In most cases, the first studies are performed 
using radiolabeled test materials (see paragraph 2.1.1). These data are used for the first 
estimation of the fate of the drug in the human body, as well as for planning human trials. 
2.3.2.1. Absorption 
The assessment of the extent and the rate of the absorption of a drug is generally based on the 
plasma concentration of the total radioactivity and/or the unchanged material. Comparing the 
results obtained after oral and intravenous administration, we can calculate the bioavailability 
of the drug. However, absorption is only one of the factors affecting bioavailability. A 
compound absorbed completely can have low bioavailability, if it undergoes intensive "first 
pass" metabolism. 
We can also have data on the extent of the absorption by calculating the area under the blood 
(plasma) curve (AUC); if we compare the elimination routes after oral and intravenous 
administration; or if we compare the parent compound content of feces and bile. 
Finally, there are several methods for the direct measurement of the absorption. 
2.3.2.1.1. Blood level monitoring of [14C]CH-13584 in rats [XIV] 
By monitoring the blood radioactivity levels in rats after different oral doses of 
[14C]CH-13584 (2, 10 and 50 mg/kg), a nearly linear absorption can be found (Figure 13.). In 
Figure 14., it can be seen that no significant gender differences could be found, but the 
absorption is somewhat slower in females. 
Comparing the area under the curve (AUC) values obtained after oral and intravenous 
administration approximately 90 % and 70 % of absorption can be seen in male and female 
rats, respectively. 
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Time [hours] 
Figure 13. Blood radioactivity levels in male rats after single oral administration of 
[ l4C]CH-13584 at the doses of 2, 10 and 50 mg/kg 
Females 2 mg/kg iv 
Males 2 mg/kg iv 
Males 2 mg/kg po 
Females 2 mg/kg po 
10 12 
Time [hours] 
Figure 14. Blood radioactivity levels in male and female rats after single oral or intravenous 
administration of [ l4C]CH-13584 at the dose of 2 mg/kg 
2.3.2.1.2. Direct measurement of absorption in rats [II] 
Direct measurement of the extent of the absorption is not a usual study; however, sometimes it 
® 
can give very useful information. When drotaverine acephyllinate (also called as Depogen ); a 
new salt form of the well-known No-Spa® was studied in rats, the so-called "in vivo loop" 
technique was used to determine if the compound is absorbed from the small intestines or not. 
The results (Table 4.) proved that drotaverine is quickly absorbed from both the duodenal and 
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ileal parts of the small intestines, if administered as theophylline-7-aeetic acid salt, directly 
into the experimental segments [II], 
C H 3 C H p 
CH3CH 
NoSpa 
O — C H p H 3 
0 - C H p H 3 
CI 
or Depogen' 
O 
0 
C H 3 » T f '*° 
// 
O ^ N - -N 
I 
CH, 
Figure 15. Chemical structure of NoSpaR and Depogen" 
Table 4. Absorption of [l4C]drotaverine acephyllinate (80 pg/sac) from duodenal and 
ileal sacs (% of the dose administered, mean ± SD) [II] 
Experimental 
segment 
10 minutes 12.5 minutes 20 minutes 30 minutes 
Duodenum 76.3 ±5.9 
N = 7 
77.6 ±8 .0 
N = 6 
82.3 ± 10.3 
N = 6 
88.5 ±2.9 
N = 7 
Ileum 68.0 ±3.3 
N = 5 
82.1 ±6 .2 
N = 6 
84.2 ± 4.6 
N = 7 
92.4 ±3.4 
N = 7 
2.3.2.2. Distribution 
Understanding the organ and tissue distribution of a drug administered is very important due 
to several reasons. First, it is important if the pharmacologically active material reaches the 
target organs or tissues. Then, as a support for toxicological studies, it can be tested which 
organs or tissues are exposed by the test material or its metabolites. Finally, the rate of the 
distribution is a significant factor concerning the course of the plasma levels of the test 
material. 
Two main methods are used to determine the tissue distribution of a drug. 
Whole body autoradiography is an attractive method. Autoradiograms (visualized 
radioactivity maps) show the localization of the radioactive material representing the studied 
drug and its metabolites. These autoradiograms are made by exposing X-ray film or other 
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radiation-sensitive layer, or by direct measurement of radioactivity visualized by computers 
(Berthold Digital Autoradiograph). However, it is only a qualitative or semi-quantitative 
method, despite of the efforts devoted to make it quantitative. 
The second technique is based on the direct radioactivity measurement of the organs and 
tissues. Certainly, special methods, such as digestion (solubilization), decolorization, and 
combustion are necessary to make the organs and tissues measurable by the liquid scintillation 
counter. This method, however, is quantitative. 
2.3.2.2.1. Whole body autoradiography of [14C]CH-13584 in rats [XV] 
Distribution of radioactivity was studied in male and female, as well as in pregnant female 
Wistar rats. Ten mg/kg single oral dose was applied. 
The results suggested rapid and intense penetration of radioactivity into the tissues and organs. 
The highest levels were detected in the gastrointestinal tract, hypophysis and thyroid gland. 
The initial rapid penetration was followed by a rapid elimination. High radioactivity levels 
could be detected only in the liver, kidneys and urinary bladder, in the so-called excretory 
organs. Twenty-four hours after the administration, the elimination of radioactivity was 
practically complete. No radioactivity could be found in the brain, however, radioactivity 
penetrated the placenta. 
Among the autoradiograms prepared in this study, only three are presented. In order to help 
recognizing the organs, the photo of the same sections can be also seen below the whole-body 
autoradiograms. 
Figure 16. shows the autoradiogram of a male rat obtained 0.5 hour after a single oral 
treatment with [14C]CH-13584. Figure 17. shows the autoradiogram of a female rat obtained 
3 hours after the treatment, while Figure 18. shows the autoradiogram of a pregnant dam 
obtained 1 hour after the treatment. 
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Liver Adrenals Brain Kidneys Testis Heart 
Brain Heart Liver Adrenals Kidneys Testis 
Figure 16. Whole body autoradiogram and the native photograph of a male rat obtained 
0.5 hour after single oral treatment with [14C]CH-13584 
Brain Liver Stomach Kidneys Intestine 
Brain Lungs Liver Intestine Kidneys 
Figure 17. Whole body autoradiogram and the native photograph of a female rat obtained 
3 hours after single oral treatment with [14C]CH-13584 
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Lungs Liver Stomach Kidneys Fetuses Intestines 
Lungs Liver Stomach Kidneys Fetuses Intestines 
Figure 18. Whole body autoradiogram and the native photograph of a pregnant dam obtained 
1 hour after single oral treatment with [14C]CH-13584 
2.3.2.2.2. Quantitative tissue distribution of [14C]CH-13584 in rats [XIV] 
Male and female Wistar rats were treated orally with 10 mg/kg dose of [14C]CH-13584. Half 
an hour, 3, 6 and 24 hours after the treatment the animals were sacrificed, and the following 
organs and tissues were removed and measured for radioactivity: brain, heart, lungs, spleen, 
liver, kidneys, adrenals, thymus, stomach, small and large intestines, sexual organs (testis or 
ovaries), muscle and fat. Before measurement of radioactivity, the tissues were homogenized 
in saline solution using a blade homogenizer, then the aliquots were solubilised in Soluene 
350®. 
The results (Table 5.) are in good accordance with the whole body autoradiography pictures. 
They confirm that the orally administered test material can be found mainly in the organs of 
the gastrointestinal tract (stomach, small and large intestines), as well as in the excretory 
organs (liver and kidneys). The test material hardly penetrates through the blood-brain barrier. 
Within 24 hours after the administration, the administered test material is practically 
eliminated from the body. 
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Table 5. Organ and tissue radioactivity levels after oral administration of 10 mg/kg 
[14C]CH-13584 to rats 
RADIOACTIVITY 
0.5 hour 3 hours 
Organs pgEq./g S.D. pgEq./g S.D. 
Brain 1.29 ± 0.18 0.22 ± 0.05 
Lungs 6.00 ± 0.58 0.72 ± 0.24 
Heart 5.94 ± 1.05 0.67 ± 0.25 
Spleen 5.91 ± 0.82 0.49 ± 0.24 
Liver 8.95 ± 0.96 1.29 ± 0.49 
Kidneys 21.48 ± 8.68 3.24 ± 0.85 
Adrenals 8.41 ± 2.01 1.72 ± 1.05 
Thymus 5.82 ± 0.47 0.71 ± 0.22 
Stomach 145.89 ± 87.06 3.84 ± 3.21 
Small intestines 13.56 ± 3.79 4.51 ± 2.79 
Large intestines 5.84 ± 0.94 14.46 ± 6.87 
Sexual organs 3.50 ± 0.74 0.83 ± 0.34 
Radioactivity 
6 hours 24 hours 
Organs UgEq./g S.D. pgEq./g S.D. 
Brain 0.05 ± 0.02 0.00 ± 0.00 
Lungs 0.11 ± 0.04 0.02 ± 0.00 
Heart 0.09 ± 0.02 0.00 ± 0.00 
Spleen 0.07 ± 0.04 0.02 ± 0.00 
Liver 0.31 ± 0.09 0.07 ± 0.04 
Kidneys 0.25 ± 0.11 0.04 ± 0.02 
Adrenals 0.83 ± 0.49 0.07 ± 0.05 
Thymus 0.09 ± 0.04 0.02 ± 0.00 
Stomach 0.62 ± 1.21 0.09 ± 0.13 
Small intestines 0.43 ± 0.72 0.04 ± 0.02 
Large intestines 13.52 ± 9.19 0.18 ± 0.09 
Sexual organs 0.11 ± 0.05 0.00 ± 0.00 
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2.3.2.2.3. Distribution of selegiline in rat brain [VI, VII] 
Selegiline is a selective MAO-B inhibitor used in the treatment of Parkinson's disease, 
However, its additional pharmacological effects, such as inhibition of dopamine uptake, some 
amphetaminergic effects, neuroprotection, antiapoptopic effects, neuronal rescue effect, [VII] 
etc., were revealed which could hardly be explained by the MAO-B inhibitory activity. Some 
of them could be attributed to the metabolism of deprenyl, but some of them are still unclear. 
For these reasons it was important to examine in details the distribution of selegiline and its 
metabolites in the brain. 
For the experiments, a mixture of tritium-labelled and 14C-labelled selegiline preparations was 
used (see paragraph 2.1.1.3). The technique for the determination of radioactivity in the 
cerebral tissues was practically the same as described in paragraph 2.3.2.2.2. with the 
exception that 3H and 14C were measured parallelly. 
The following cerebral tissues were dissected and measured from the rats treated with 
selegiline at the oral dose of 1.5 mg/kg: bulbus olfactorius, cerebellum, colliculus superior, 
corpus pineale, corpus striatum, frontal cortex, hippocampus, hypophysis, hypothalamus, 
medulla oblongata, nucleus mamillaris, parietal cortex, pons + colliculus inferior, substancia 
nigra, tuberculum olfactorium. The distribution of radioactivity in brain was tested 0.25, 0.5, 
0.75,1,2,4, 6, 8,12, 24,48, 72 and 96 hours after drug intake. 
Table 6. AUCo-96 values of cerebral tissues from rats treated orally with 1.5 mg/kg selegiline 
Tissues AUCo-96
 3H 
[pmol/mg/h] 
AUCo-96 14C 
[pmol/mg/h] 
3H to 14C ratio 
[ - ] 
Plasma 107.89 33.59 3.2 
Corpus pineale 133.70 0 
Bulbus olfactorius 100.70 45.1 2.2 
Hypophysis 55.25 33.27 1.7 
Hypothalamus 166.31 48.92 3.4 
Tuberculum olfactorium 137.32 55.13 2.5 
Substancia nigra 152.56 0 
Nucleus mamillaris 116.56 0 
Frontal cortex 159.89 34.26 4.7 
Parietal cortex 122.64 37.45 3.3 
Corpus striatum 70.34 23.41 3.0 
Hippocampus 118.62 32.18 3.7 
Colliculus superior 189.71 56.31 3.4 
Cerebellum 183.90 50.46 3.6 
Pons+Colliculus inferior 147.08 38.92 3.8 
Medulla oblongata 143.92 37.63 3.8 
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In all of the cerebral tissues examined, the molar concentration of 3H-labelled compounds 
representing selegiline and its metabolites containing phenyl group (e.g. methamphetamine, 
amphetamine, desmethyl-selegiline, etc.) is higher than the molar concentration of Re-
labelled compounds representing selegiline and its metabolites containing propargyl group 
(e.g. desmethyl-selegiline, propiolaldehyde, propargylamine, etc.). These results show that 
considerable quantity of metabolites are formed, already by "first pass" metabolism, and N-
despropargyl derivatives of selegiline are dominant in the cerebral tissues. 
2.3.2.2.4. In vitro and in vivo binding of CH-13584 to serum (plasma) proteins [XV] 
Using an Amicon 8MC ultrafiltration system and 14C-labelled CH-13584 preparation, protein 
binding of CH-13584 was studied by simple ultrafiltration technique, in vitro and in vivo in 
rats, and in vitro in human. 
In the in vitro experiment a concentration series of 0.01, 0.025, 0.05, 0.1, 0.25, 0.5, 1.0,2.5, 5, 
25 and 50 mg/L CH-13584 was applied. The results of the protein binding study can be seen 
in Table 7. The results show that no significant protein binding of CH-13584 occurs in rat and 
human plasma in vitro. 
For the in vivo study, Wistar rats were administered with 10 mg/kg oral dose of 
[14C]CH-13584, and blood samples were taken 1 and 3 hours after dosing. Plasma was 
obtained by centrifugation, and the same equipment was used for the determination of the 
binding to plasma proteins. The average plasma concentrations were 3.5 ± 0.3 and 
0.3 ±0.1 mgEq./L 1 and 3 hours after the treatment, respectively. The unbound fraction was 
86.5 ± 1.5 and 71.3 ± 6.8 % on the average. The results suggest that the metabolites formed 
from CH-13584 are bound to plasma proteins at a somewhat higher percentage than the parent 
compound, but this level of binding is practically still not significant. 
Table 7. In vitro binding of [14C]CH-13584 to rat and human plasma proteins 
Concentration of 
[14C] CH-13584 
[mg/L] 
Unbounc 
Rat plasma 
% 
1 fraction 
Human plasma 
% 
0.010 100.31 90.12 
0.025 90.19 94.50 
0.050 90.43 90.96 
0.100 88.77 93.34 
0.250 84.66 90.09 
0.50 86.05 95.90 
1.00 87.21 93.24 
2.50 88.96 91.26 
5.0 86.95 92.97 
25.0 83.89 88.20 
50.0 86.18 87.45 
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2.3.2.3. Excretion 
For safety reasons, it is very important that the test material is eliminated from the body within 
a certain period. In any case, a drug have to be excreted after exerting its effect, otherwise it is 
impossible, or at least very difficult to regulate its action. A drug having long-lasting 
elimination can have long-lasting pharmacological effect, too, but it also can be cumulated in 
the body, especially in an organ, and it can cause unwanted side effects. 
Not only the rate but also the route of the excretion is important. The two main routes are the 
urine, through the kidneys, and the bile, through the liver. The drug or its metabolites excreted 
in bile can be eliminated via feces, or can be reabsorbed from the intestines (entero-hepatic 
circulation). 
There are some other routes for the elimination of a drug, such as the sweat, saliva, breast 
milk, expired air, but generally, these routes are not significant. However, one of these routes, 
namely the expired air is studied very frequently. The radioactive test material — following a 
metabolic reaction — can loose the [14C] in the form of [14C]carbon dioxide, and then not the 
test material or its metabolites, but only a small fragment of the molecule is monitored. 
Practically, the measurement of radioactivity in the expired air is a kind of control of the 
synthesis of the radiolabeled material. If significant amount of radioactivity can be found in 
expired air, the position of the radioactive nuclide was not appropriately designed. 
2.3.2.3.1. Mass balance of [14C]CH-13584 in rats [XIV] 
Urine, feces and expired air were collected in 24-hour fractions from male and female rats 
treated orally with 10 mg/kg of [14C]CH-13584. Radioactivity of the samples was measured 
by liquid scintillation counting. Practically no radioactivity could be detected in the expired 
air; less than 0.01 % of the dose could be found within 168 hours. 
The mass balance of [I4C]CH-13584 administered to rats can be seen in Figure 19. and Figure 
20. The majority of the radioactivity was excreted with urine; within 168 hours, 87.12 ± 8.43 
and 78.64 ± 8.34 % of the dose could be recovered in the urine in males and females, 
respectively. Within the same period, the fecal elimination of the radioactivity was 
13.24 ± 7.70 and 11.17 ± 4.84 % of the dose, thus the total recovery was 98.31 ± 6.06 and 
91.91 ± 2.46 % of the dose in males and females, respectively. 
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Figure 19. Urinary and fecal elimination of radioactivity after single oral administration of 
[UC]CH-13584 to male rats 
II Urine Time [hours] 
Figure 20. Urinary and fecal elimination of radioactivity after single oral administration of 
[14C]CH-13584 to female rats 
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2.3.2.3.2. Urinary elimination of [UC]DIMEB in rats [IV] 
There are certain cases, when the method used regularly for studying urinary elimination of a 
test material is not appropriate to characterize its pharmacokinetic features. It was the case, 
when pharmacokinetics of heptakis-(2,6-di-(9-methyl)-|3-cyclodextrin (DIMEB), a potential 
agent for increasing the solubility of poorly water soluble drugs by forming inclusion 
complexes, were studied. 
Since some cyclodextrins may have tissue-damaging effect, it was crucial to demonstrate that 
DIMEB has a very short residence time in the body. Preliminary results showed, that in rats, 
80-90 % of the dose was eliminated within 72 hours in urine after a single intravenous 
administration of [I4C]DIMEB. 
Continuous urine collection, or serial collection of urine in short time intervals is relatively 
easy in human and in bigger laboratory animals such as dogs, using a catheter. The technique, 
however, was not developed for small laboratory animals, and especially for rats. Using a new 
surgical technique, the collection of urine samples in one-hour fractions from not 
anaesthetized, unrestricted rats was performed [IV]. Analyzing the fractions, the very rapid 
excretion of DIMEB was proven from the systemic circulation into urine. More than 50 % of 
the dose was found in the first (0-1 hour) urine fraction and more than 70 % was excreted 
within 3 hours (Figure 21.). 
100 n 
New technique 
•Traditional technique 
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72 
Figure 21. Urinary elimination of DIMEB in rats after intravenous administration 
2.3.3. Metabolism 
Metabolism of drugs and the role of liver microsomal enzymes have been already discussed in 
paragraph 2.2.3. 
The metabolic steps can be divided into two main groups. By the phase 1 metabolic reactions, 
which are generally oxidative reactions, the chemical structure of the lipophilic drugs is 
modified to form biotransformation products (metabolites), which are more polar, more 
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hydrophylic compounds. The most common reactions are oxidation, hydroxylation and the 
oxidative N- or O-dealkylation. During metabolic processes, the oxidative reactions are 
usually followed by conjugation reactions resulting in polar conjugates that are easily 
excreted. The most common conjugation reaction (phase 2 metabolic reaction) is catalyzed by 
UDP-glucuronyltransferases. Beside these glucuronide conjugates, formation of glutathion-, 
sulphate- and methyl conjugates can also be observed. 
The aim of the metabolism studies in the preclinical development phase of the drug is to 
determine the main metabolic routes by identifying the chemical structure of the metabolites. 
Some years ago, the separation (TLC, HPLC, column chromatography) and isolation 
(scrapping from TLC, fraction collection after HPLC or column chromatography) of the 
metabolites were necessary for the identification of the chemical structure using MS, NMR, 
IR and/or Raman spectroscopy. Nowadays, when LC-MS/MS and LC-NMR equipment are 
available, the structure elucidation of the metabolites is much less time-consuming. 
Nevertheless, there are cases when new metabolites are identified many years after a drug is 
launched. It must be noted here, that a metabolite can be considered as identified if it was 
synthesized, and the chromatographic, mass spectrometry and NMR characteristics of the 
synthesized reference standard are identical with those of the metabolite. 
2.3.3.1. Metabolism of CH-13584 in rat, dog and guinea pig [XII, XVII] 
Metabolism of CH-13584 was investigated in rats, dogs and guinea pigs. Practically, only 
unchanged CH-13584 could be detected in plasma in all animal species studied. Urine 
samples were analyzed by HPLC, and twelve metabolites were found in the chromatograms. 
The ratio of the metabolites showed considerable individual variation, but it also showed 
significant sex difference in the case of dogs (Table 8). Except female dogs, unchanged CH-
13584 was found mainly in the urine; an average of 68.7, 94.0 and 74.8 % of the total 
metabolites excreted in urine was found unchanged in rats, guinea pigs and male dogs, 
respectively. Beside the parent drug, M3, M4, M5 and M10 metabolites represented 
considerable amounts. In the case of female dogs, M4 was the main urinary metabolite. 
Out of the twelve metabolites, the chemical structure of four ones could be identified, and the 
chemical structure of one metabolite could be suspected [XVII]. 
Accordingly, M i l was found to be the unchanged CH-13584, M5 was a metabolite where the 
oxadiazole ring was opened (3-methyl-7-acetamidoxanthine), M6 was identified as 3-
methylxanthine, M8 was found to be the 3-desmethylated derivative of CH-13584, and M4 
was supposed to be xanthine. The metabolic pathways are demonstrated in Figure 22. 
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Table 8. Elimination of CH-13584 and its metabolites in rat, dog and guinea pig urine 
(Relative %) 
Rats Guinea pigs Dc >gs 
Metabolites (N= =6) (N= =2) Males (N=3) Female s (N=3) 
(M) Mean SD Mean SD Mean SD Mean SD 
1-2 0.0 0.0 0.0 0.0 0.3 0.3 1.0 0.9 
3 4.7 9.2 0.3 0.0 1.5 1.4 19.1 28.4 
4 14.0 20.0 0.4 0.3 11.6 7.9 32.2 14.8 
5 4.4 1.9 0.3 0.2 5.2 0.2 17.4 6.8 
6 1.3 0.6 0.2 0.0 0.5 0.1 0.0 0.0 
7 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 
8 0.2 0.3 0.1 0.2 5.5 3.4 0.8 1.1 
9 1.1 1.9 4.0 0.0 0.3 0.3 0.0 0.1 
10 4.6 7.3 0.0 0.0 0.0 0.0 8.8 8.3 
11 68.7 27.1 94.0 0.2 74.8 5.9 14.7 16.1 
12 1.0 2.0 0.4 0.1 0.3 0.3 6.0 8.8 
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Figure 22. Metabolic pathways and structure of the identified metabolites of CH-13584 
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2.3.3.2. Metabolism of selegiline [V, XI] 
CH-13584 is a drug, which is rather stable in the organisms, and which has relatively simple 
metabolism pathway. The majority of the compounds is not as such. 
Selegiline (also called as (-)-deprenyl, or L-deprenyl), chemically (-)-N, a-dimethyl-7V-2-
propynylbenzeneethanamine, is a selective and irreversible inhibitor of monoamine oxidase 
type B. It is widely used in the treatment of Parkinson's disease. Selegiline is an original 
CHINOIN drug, however, its pharmacology, pharmacokinetics and metabolism, as well as its 
clinical characterization were mainly studied out of CHINOIN, generally on a contract basis, 
or by the license partners. 
Although racemic selegiline was discovered in 196229 and its optical isomers were 
synthesized and patented in the middle of the sixties30, the first pharmacokinetic and 
metabolism results were published only six-ten years later [XI]. The main metabolites of 
selegiline, such as desmethylselegiline, methamphetamine and amphetamine were discovered 
very early, while minor metabolites were identified much later. Because of the success of 
selegiline, and because of its unique pharmacology, after almost forty years, studies are still 
being performed; newer and newer clinical advantages are recognized; new minor metabolites 
are identified. Among the metabolites of selegiline, p-hydroxyl-desmethylselegiline, p-
hydroxyl-amphetamine, /?-hydroxyl-methamphetamine, iV-acetylamphetamine, norephedrine 
and nor-pseudoephedrine, ephedrine and pseudoephedrine, phenylacetone and phenylacetone-
oxime were identified as minor ones in animal species or in human. Selegiline-TV-oxide could 
be recently identified as a metabolite of selegiline (see paragraph 2.3.3.2.1). The metabolic 
pathways of selegiline, as well as its putative metabolites supposed on theory or analogy can 
be seen in Figure 23. 
2.3.3.2.1. Identification of selegiline-TV-oxide as a metabolite of selegiline [XIX, XX] 
Based on analogy, the formation of selegiline-TV-oxide was supposed already in the 
eighties31,32. Later, when pharmacokinetic and metabolic characterization of selegiline was 
performed using a quasi-double-labelled radioactive preparation (see paragraph 2.1.1.3), we 
found an unknown metabolite, which contained both the propargyl and the "amphetamine" 
parts. However, when the metabolite was injected into the gas chromatograph, it always 
underwent a decomposition process forming selegiline. Then, we had the hypothesis that the 
unknown metabolite was selegiline-JV-oxide. Chemists of CHINOIN Preclinical Development 
synthesized selegiline-TV-oxide (both R,R and R,S diastereomers, because stereoselective N-
oxidation was published for pargyline, a chemically very similar MAO inhibitor ), and thus, 
selegiline-TV-oxide could be identified as a metabolite of selegiline. The formation of 
selegiline-TV-oxide in liver microsomal preparations obtained from different animal and 
human species shows rather big differences. While significant amount of selegiline-TV-oxide 
was found in dog and hamster microsomes, less amount was detected in mice, rats, guinea 
pigs and rabbits, and only very little selegiline was metabolized to its TV-oxide derivative in 
human preparation (Table 9.). 
In microsomal preparations obtained from animal and human species studied, except of 
hamster, the in vitro formation of the R,S diastereomer of selegiline-TV-oxide was preferred 
(57.7-81.8%). 
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Figure 23. Metabolites of selegiline identified in animal species and in human (bold blue), as well as its putative metabolite pathway 
supposed on theory or analogy (green) [XI] 
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Table 9 The ratio of the metabolites of selegiline after incubation in liver microsomal 
preparations from different species (in % of peak area of selegiline measured in 
0 minute-samples) 
Species AMP MET DES SEL SNO TOT 
Rat 12.5 27.7 21.4 0.6 20.2 82.4 
Dog 6.3 25.4 2.6 0.0 55.6 89.8 
Hamster 15.5 2.4 0.0 0.0 41.2 59.1 
Rabbit 14.7 9.5 12.1 20.2 14.4 71.0 
Mouse 13.0 28.9 20.1 3.9 21.5 87.5 
Guinea pig 24.0 42.2 0.0 0.0 19.8 86.0 
Human 0.0 15.2 9.9 74.6 1.0 100.6 
AMI ^ amphetamine, MET=methamphetamine, DES=desmethy selegiline, 
SEL=selegiline, SNO=selegiline-A-oxide, TOT=total recovery as "main" metabolites 
2.4. CLINICAL PHARMACOKINETICS AND METABOLISM 
The aim of the clinical pharmacokinetic and metabolism studies is to clarify if the drug, which 
was already examined in non-clinical systems in details, is absorbed, reaches a certain level in 
the plasma, is eliminated within a certain time, if it is safe to use in men. The majority of the 
pharmacokinetic and metabolism methods used in the clinical studies are similar to those used 
in the preclinical ones. In fact, the pharmacokinetic evaluations are based on bioanalytical 
measurements of the unchanged compound and its metabolites in plasma, urine and feces 
samples obtained from subjects treated with the drug. 
Among the clinical pharmacokinetic and metabolism studies, single and multiple dose 
tolerance studies (Phase 1), single and multiple dose pharmacokinetic studies, mass balance 
and metabolite identification studies (Phase 2), pharmacokinetics in patients with renal or 
liver disease, formulation bioavailability, drug-drug interaction studies can be mentioned. 
However, depending on the drugs studied, or on the therapeutic field aimed, other 
investigations can also be performed, or some of the studies can be carried out within one 
study. 
2.4.1. Human pharmacokinetics of drotaverine-acephyllinate [III] 
Drotaverine-acephyllinate34 (also called as Depogen®), is a drug having peripheral vasodilator 
and spasmolytic effects, similarly to NoSpa®, a core product of CHINOIN. In fact, Depogen® 
is the theophylline-7-acetic acid salt of drotaverine (Figure 15.). Its pharmacokinetic 
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characteristics were studied in seven male healthy volunteers, using l4C-labelled preparation, 
where the 14C label was in the drotaverine part of the molecule. The applied dose was 100 mg 
in a hard gelatine capsule. 
Figure 24. shows the radioactivity concentrations in blood and plasma, while Figure 25. 
demonstrates the radioactivity and unchanged drotaverine concentrations in plasma. 
The results showed that peak plasma concentration was reached between 0.75 and 1 hour after 
drug administration. Plasma and blood radioactivity curves showed an almost identical course. 
The unchanged drug and its metabolites were not bound to blood cells. 
Figure 24. Average plasma and blood radioactivity concentrations in men after single oral 
administration of [14C]drotaverine acephyllinate 
Figure 25. Average radioactive and unchanged drotaverine concentrations in human plasma 
after single oral administration of [l4C]drotaverine acephyllinate 
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The parent drug concentrations were about one-fifth of the total radioactivity concentrations. 
Drotaverine part of Depogen® was almost completely metabolized by O-desethylation to 
mono- and diphenolic moieties, and these metabolites were rapidly conjugated with 
glucuronic acid. 
As in can be seen in Figure 26., almost equal portions of the administered dose were 
eliminated in urine and feces (39.0 ± 9.9 and 47.1 ± 4 . 9 % of dose, respectively, within 72 
hours). The total recovery within 72 hours was 86.1 ± 10.1 % of the administered dose. 
0 24 48 72 
Time [hours] 
Figure 26. Cumulative urinary and fecal elimination of radioactivity after single oral 
administration of [l4C]drotaverine acephyllinate 
2.5. I N T E R A C T I O N S T U D I E S [VIII] 
As it was discussed earlier (2.2.3), CYP450 enzymes play an important role in the 
biotransformation of lipophilic drugs. Any changes in the activity of CYP450 isoenzymes may 
influence the rate of activation (if the metabolite is more active than the parent compound) or 
inactivation (if the metabolite is less active than the parent compound) of drugs. 
Consequently, if a drug induces or inhibits one or more CYP isoenzymes, it can modify the 
pharmacological and/or the safety profile of another drug metabolized by the affected isoform. 
It must be mentioned that pharmacokinetic interactions cannot exclusively be related to 
metabolism, but also to protein binding, absorption or elimination. 
Ipriflavone (also called as OSTEOCHIN®), a synthetic flavonoid, was developed for treatment 
of osteoporosis. In the case of a Japanese patient, who took regularly theophylline for chronic 
obstructive pulmonary disease, an increase in the theophylline serum concentration was 
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observed when ipriflavone was concomitantly administered. After withdrawal of ipriflavone, 
theophylline serum level was decreased. It was clear that metabolism of theophylline was 
altered by ipriflavone35. 
In an in vitro interaction study, we examined which CYP450 isoenzymes could be responsible 
for the in vivo interaction of theophylline and ipriflavone [VIII]. 
Using human liver microsomal preparation, the effect of ipriflavone and its two main human 
metabolites, 7-hydroxyisoflavone and 7-(l-carboxyethoxy)isoflavone, on the activity of 
CYP450 isoenzymes, such as CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 
and CYP3A4 was examined. The isoenzyme activities were monitored by measuring the 
metabolism of selective substrates of the isoenzymes. Inhibitory effect of ipriflavone and its 
two main metabolites were expressed as the percentage of the control incubation (without 
ipriflavone or metabolite). 
The results showed that ipriflavone and 7-hydroxyisoflavone had inhibitory effects on 
phenacetine O-desethylase (CYP1A2) and tolbutamide hydroxylase (CYP2C9), while the 
main human metabolite, 7-(l-carboxyethoxy)isoflavone did not alter the activities of the 
CYP450s investigated. Since CYP2C9 is not an isoenzyme, which catalyzes any step of 
theophylline metabolism, it cannot be responsible for the interaction between ipriflavone and 
theophylline. However, CYP1A enzymes are known to be involved in the metabolism of 
methylxanthines, especially in their W-demethylation. Thus, it can be supposed that — in the 
case of the Japanese patient mentioned above35 — ipriflavone and one of its main metabolites, 
7-hydroxyisoflavone, inhibited V-demethylation of theophylline through CYP1A2 inhibition. 
It must be noted, that no other case of interaction caused by ipriflavone was reported. 
2.6. DEVELOPMENT OF NEW FORMULATIONS [X] 
An appropriate formulation can change not only the physical but also the pharmacokinetic or 
therapeutic characteristics of a drug. It can increase the bioavailability (e.g. by increasing 
solubility) of a drug36'37; it can provide the controlled release of the active ingredient (once-a-
day formulations)9. Sometimes the new formulation also means new administration route, at 
the same time, for example, preparation of suppositories or transdermal38'39 formulations is 
rather common in the pharmaceutical industry. This was the case in CHINOIN with selegiline, 
a drug used successfully in the Parkinson's disease40'41 [X]. 
From simple ointments through transdermal silicon patch, to liposome formulations [X], 
several transdermal formulations were prepared and examined. Moreover, a new two-phase 
formulation — based on the mechanism of action of selegiline — was also developed42. 
The pharmacokinetic effort in these studies always had two targets. On one hand, the 
pharmacokinetic profile requested should be tested; on the other hand, the bioavailability of 
the active ingredient had to be determined in different species. Sometimes, when the 
equivalence of the "old" and "new" formulation was declared, bioequivalence studies were 
performed. 
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3. SUMMARY 
In the last ten-fifteen years, pharmacokinetic and metabolism studies became essential part of 
the drug research and development; they overlap the discovery, preclinical and clinical phases. 
Early in the nineties, we developed a system for pharmacokinetic and metabolism studies, 
based on regulations, guidelines, international tendencies, traditions and capabilities. The 
system described the pharmacokinetic and metabolism studies to be performed in the 
discovery phase (Figure 27.), and we also put a screen into practice (in vitro absorption, in 
vitro metabolism), in order to help the selection of new drug candidates. The system involved 
the pharmacokinetic and metabolism studies to be performed in the preclinical development 
phase (Figure 28.). We established an animal experimental unit, where studies required for the 
registration of the drug can be performed according to the standards. The laboratory got a 
certificate from the Hungarian registration authority (OGYI) in 1997, which certificate 
declares the compliance of the laboratory with the principle of the Good Laboratory Practice 
(GLP). The system also included the pharmacokinetic and metabolism studies to be performed 
in the clinical development phase (Figure 29.), and we could implement a bioanalytical 
background with bioanalytical specialists and equipment, thus we have a facility in 
compliance with the principles of Good Clinical Practice (GCP). 
So the main result of my activity described in this paper, that there is a working system, a 
well-operating organization in CHINOIN R&D, with thirteen people at this time. Colleagues 
can perform practically all kind of pharmacokinetic studies required from the very beginning 
of drug discovery up to the registration of a new drug, and beyond. We recognized that to 
characterize a new drug for the pharmacokinetics and metabolism is always a scientific 
novelty. 
In this paper, I showed selected examples on the studies performed with compounds 
developed in CHINOIN. Some of them were performed earlier than the new system was 
established, but the majority was carried out in the last ten years. For that very reason, these 
selected examples are excellently suitable to demonstrate the change in the pharmacokinetic 
and metabolism approach carried out in CHINOIN R&D in accordance with the international 
practice. One of the main aims of this paper was to show how this change in the paradigm 
appears in the daily work. 
• I stressed the importance of the bioanalytical activity, including the separation 
techniques and the use of radiolabeled materials. 
• I introduced the in vitro absorption and metabolism screens, and how these screens can 
help the drug discovery. I proved the importance of these screens in the selection of 
the pharmacological species. I demonstrated the chemical structure and metabolic 
stability relationship through the example of prolylendopeptidase inhibitors. 
• I presented results on the preclinical pharmacokinetic and metabolism of CH-13584, 
an original CHINOIN antitussive agent: 
> I proved that CHINOIN-13584 is absorbed orally in rats, however, at very high 
doses, the absorption is not dose-proportional. 
> I demonstrated that CH-13584 is distributed rapidly, but it cannot pass the blood-
brain barrier. 
> I presented that the drug and its metabolites are eliminated mainly in urine, and the 
recovery of the test material is practically complete within 168 hours. 
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Figure 27. Pharmacokinetic and metabolism studies to be performed during the discovery 
phase of drug research and development 
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Figure 28. Pharmacokinetic and metabolism studies to be performed during the preclinical 
development of drug research and development 
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Figure 29. Pharmacokinetic and metabolism studies to be performed during the clinical 
development of drug research and development, as well as after registration 
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> I showed that CH-13584 is poorly metabolized in several animal species; the 
metabolic pathways are the JV-demethylation and the oxidation of the oxadiazole 
ring. 
> I demonstrated that binding of CH-13584 to plasma proteins is negligible. 
• As I mentioned earlier, special studies have to be performed sometimes, to 
characterize the test material better. I presented some results obtained from such kind 
of studies: 
> I presented that drotaverine acephyllinate (Depogen®) is rapidly absorbed from the 
duodenal and ileal parts of the small intestines. I obtained the results from a study 
using in vivo loop technique. 
> I proved that dimethyl-P-cyclodextrin (DIMEB) is eliminated very quickly from 
the body via urine. For this study, I developed and applied a rather new surgical 
technique, which was appropriate for gathering urine samples from 
unanaesthetized, unrestricted rats in short (1-hour) time fractions. 
> I proved that selegiline metabolites lost propargyl group are dominant in the rat 
brain after oral administration of selegiline. By this, I showed that beside 
selegiline, selegiline metabolites play a significant role in the pharmacological 
effect of the drug. 
> I demonstrated that the metabolic pathways of a drug can be very diverse, and the 
identification of the metabolites sometimes takes rather long time. I proved that 
selegiline-JV-oxide is a metabolite of selegiline, which was discovered twenty years 
ago, but the chemical structure could be only recently identified. 
• The results of the clinical pharmacokinetic and metabolism studies of Depogen® are as 
follows: 
> I proved that the drotaverine part of Depogen® is absorbed very quickly, and the 
peak plasma concentration is reached between 0.75 and 1 hour after oral 
administration of the 14C-labelled preparation. I demonstrated that the unchanged 
drug and its metabolites are not bound to blood cells. 
> I presented that one-fifth of the total radioactivity can be found in plasma as 
unchanged drotaverine, because it is almost completely metabolized by O-
desethylation to mono- and diphenolic compounds, and these metabolites are 
conjugated rapidly with glucuronic acid. 
> I showed that almost equal portions of the administered drotaverine acephyllinate 
are eliminated in urine and feces, and the total recovery amounts to more than 85 
% of the dose within 72 hours. 
• Among the studies performed with the drugs being on the market, I presented the 
interaction studies between ipriflavone and theophylline, and the formulation studies 
with selegiline: 
> I proved that ipriflavone, a synthetic flavonoid, and one of its main human 
metabolites can inhibit CYP 450 1A2 and 2C9 isoenzymes. 
> Within the life-cycle management of selegiline (JUMEX®), a core product of 
CHINOIN, different types of transdermal formulations, such as ointments, silicon 
patches, liposomal formulations, as well as a special two-phase formulation were 
developed and characterized. 
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